Table 1.

Patient Characteristics.

Patient ID	Sex	KPS [%]	Age [years]		Time to recurrence [months]	IDH mutation status	MGMT promotor methylation status	Ki-67 index [%]		All: Radiotherapy with concomitant TMZ (27)	Overall survival[months]
			At initial diagonsis	At recurrence				At initial diagonsis	At recurrence	Cycles of adjuvant TMZ until 2nd resection:
1	m	100	30	31	5	wildtype	–	20	30	3	27.8
2	f	70	71	72	4	wildtype	+	10	>5	1	39.6
3	m	80	66	68	8	wildtype	+	10	30	6	27.7
4	m	80	58	59	12	wildtype	+ (+/-)	10	12	3 + ISBT	17.8
5	m	80	64	65	8	wildtype	–	>5	n. a.	6	17.4
6	m	80	42	43	7	wildtype	+	50	20	6	51.2
7	m	80	49	50	6	wildtype	–	20	15	4-5	20.7
8	f	90	56	57	7	wildtype	+	20	>5	TMZ + CCNU	70.3
9	f	90	41	42	15	wildtype	+	50	n. a.	2 + 6 (i)	33.0
10	m	100	25	25	6	mutant	+	30	n. a.	3	17.7
11	f	80	66	69	33	n. a.	+	> 5	18	8 (C) + 1 (i) + 6 (i) + ISBT	59.2
12	m	80	57	59	23	wildtype	+	25	n. a.	12 (C)	51.2
13	m	80	65	66	10	wildtype	–	30	80	3 + 2 (i)	13.5
14	f	90	44	45	13	wildtype	–	20	n. a.	11	46.2
15	m	80	74	74	8	wildtype	+	>5	1	3	13.2
16	m	90	51	52	12	wildtype	–	45	n. a.	6	31.3

m, male; f, female; +, methylated; –, unmethylated; +/−, partially methylated; n. a., not available; TMZ, temozolomide; i, intensified TMZ according to DIRECTOR (28); CCNU, lomustine [according to CeTeG (29)]; C, with additional cilengitide [according to CENTRIC (30)]; ISBT, interstitial brachytherapy.